黄芪四物汤治疗实验性肺动脉高压的转录组与代谢组整合机制研究
本研究以野百合碱诱导的肺动脉高压大鼠为模型,探讨黄芪四物汤(HQSWT)对疾病预防及已建立疾病的治疗作用。通过RNA测序、转录组与代谢组整合分析及多重免疫组化和qPCR验证,发现HQSWT剂量依赖性预防PAH发生并减轻已建立的PAH、右心室肥厚和肺血管重塑,其机制涉及细胞外基质通路(Fn1、Thbs2)及ALOX5-LTB4轴调控的花生四烯酸代谢。
要点
- HQSWT剂量依赖性预防野百合碱诱导的PAH发生并减轻已建立的PAH。
- HQSWT可减轻右心室肥厚和肺血管重塑。
- HQSWT通过细胞外基质通路及ALOX5-LTB4轴发挥保护作用。
核心结论
- HQSWT对实验性PAH具有治疗作用,可能通过同时靶向细胞外基质和炎症介导的肺血管重塑发挥作用。
研究设计与样本
- 采用野百合碱诱导的PAH大鼠模型,评估HQSWT对疾病预防及已建立疾病的治疗作用。
- 运用RNA测序、整合代谢组学与转录组学分析,并通过多重免疫组化和定量PCR验证发现。
主要发现
- HQSWT剂量依赖性预防野百合碱诱导的PAH发展,并减轻已建立的PAH、右心室肥厚和肺血管重塑。
- 转录组分析显示HQSWT作用于细胞外基质通路,包括Fn1和Thbs2。
- 观察到HQSWT通过ALOX5-LTB4轴调节花生四烯酸代谢,并降低肺组织和血管周围巨噬细胞中ALOX5表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension is a complex vascular disease involving pathological remodeling of vascular cells, inflammatory cells, and the extracellular matrix. Current PAH therapies, which are primarily vasodilators, cannot reverse the disease pathogenesis or cure PAH. Novel therapeutic agents targeting the core process of vascular remodeling are desperately needed, and their mechanisms warrant systematic investigation. PURPOSE: This study aimed to investigate the therapeutic potential of Huang-Qi-Si-Wu-Tang (HQSWT), a traditional Chinese herbal formula, in experimental models of PAH and to elucidate its underlying mechanisms. METHODS: We used monocrotaline-induced PAH in rats as an experimental model. We assessed the effect of HQSWT on disease prevention, as well as its effect in mitigating established disease. We employed RNA sequencing, integrated metabolomics and transcriptomics analysis, and validated findings by multiplex immunohistochemistry and quantitative PCR. RESULTS: HQSWT dose-dependently prevented monocrotaline-induced PAH development and mitigated established PAH, right ventricular hypertrophy, and pulmonary vascular remodeling. Transcriptomic analysis revealed HQSWT's action on extracellular matrix pathways, including Fn1 and Thbs2. Furthermore, we observed modulation of arachidonic acid metabolism via the ALOX5-LTB4 axis. HQSWT reduced ALOX5 expression in lung tissue and perivascular macrophages. CONCLUSION: Our results demonstrate that HQSWT is effective in treating experimental PAH. Through omics analysis, we have identified a novel mechanism of action whereby HQSWT may exert its protective effects by simultaneously targeting the extracellular matrix and inflammation-mediated pulmonary vascular remodeling, suggesting its potential as a new therapy for PAH.
引用
- Wang Y, Guo Z, Ma X, et al. Integrated transcriptome and metabolome analysis reveals the therapeutic mechanism of Huang-Qi-Si-Wu-Tang in experimental pulmonary arterial hypertension. Phytomedicine. 2025. PMID: 40651300. doi:10.1016/j.phymed.2025.157058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。